Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Fixed-dose enoxaparin provides efficient DVT prophylaxis in mixed ICU patients despite low anti-Xa levels: A prospective observational cohort study

J. Benes, R. Skulec, J. Jobanek, V. Cerny

. 2022 ; 166 (2) : 204-210. [pub] 20210527

Language English Country Czech Republic

Document type Journal Article, Observational Study

Persistent link   https://www.medvik.cz/link/bmc22014548

BACKGROUND: Deep vein thrombosis (DVT) is a serious but preventable complication of critical illness with a reported incidence from 4 to 17%. Anti-Xa activity in critically ill patients achieved with standard dosing of low-molecular-weight heparins (LMWH) is often below the target of 0.2-0.5 IU/mL. However, the clinical significance of this finding is unclear. The quality of thromboprophylaxis also strongly impacts the incidence of DVT. We performed a prospective observational study to evaluate the incidence of DVT in a mixed medical-surgical-trauma intensive care unit (ICU) using a thromboprophylaxis protocol with a fixed dose of enoxaparin. We also explored the relation between DVT incidence and anti-Xa activity. METHOD: All consecutive patients with expected ICU stay ≥72 hours and without evidence of DVT upon admission were included. They underwent ultrasound screening for DVT twice a week until ICU discharge, death, DVT or pulmonary embolism. Peak anti-Xa activity was measured twice a week. Patients received 40 mg of enoxaparin subcutaneously (60 mg in obese, 20 mg in case of renal failure). Graduated compression stockings were used in case of LMWH or another anticoagulant contraindication. RESULTS: A total of 219 patients were enrolled. We observed six cases of DVT (incidence of 2.7%). The agreement between expected and delivered DVT prophylaxis was 94%. Mean peak anti-Xa activity level was 0.24 (SD, 0.13) IU/mL. There was no significant difference in anti-Xa activity in DVT and non-DVT group. CONCLUSION: A low incidence of DVT was achieved with meticulous adherence to the standard prophylactic protocol. The low incidence of DVT was observed despite low levels of anti-Xa activity. Our findings suggest that enoxaparin dose adjustment based on regular monitoring of anti-Xa activity is unlikely to result in further reduction of DVT incidence in a mixed ICU population. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03286985.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22014548
003      
CZ-PrNML
005      
20230308093752.0
007      
ta
008      
220602s2022 xr f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2021.031 $2 doi
035    __
$a (PubMed)34042098
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Beneš, Jan $u Faculty of Medicine in Hradec Kralove, Charles University in Prague and University Hospital Hradec Kralove, Czech Republic $u Deartment of Anesthesiology, Perioperative Medicine and Intensive Care Masaryk Hospital, J.E. Purkinje University, Usti nad Labem, Czech Republic $7 xx0232585
245    10
$a Fixed-dose enoxaparin provides efficient DVT prophylaxis in mixed ICU patients despite low anti-Xa levels: A prospective observational cohort study / $c J. Benes, R. Skulec, J. Jobanek, V. Cerny
520    9_
$a BACKGROUND: Deep vein thrombosis (DVT) is a serious but preventable complication of critical illness with a reported incidence from 4 to 17%. Anti-Xa activity in critically ill patients achieved with standard dosing of low-molecular-weight heparins (LMWH) is often below the target of 0.2-0.5 IU/mL. However, the clinical significance of this finding is unclear. The quality of thromboprophylaxis also strongly impacts the incidence of DVT. We performed a prospective observational study to evaluate the incidence of DVT in a mixed medical-surgical-trauma intensive care unit (ICU) using a thromboprophylaxis protocol with a fixed dose of enoxaparin. We also explored the relation between DVT incidence and anti-Xa activity. METHOD: All consecutive patients with expected ICU stay ≥72 hours and without evidence of DVT upon admission were included. They underwent ultrasound screening for DVT twice a week until ICU discharge, death, DVT or pulmonary embolism. Peak anti-Xa activity was measured twice a week. Patients received 40 mg of enoxaparin subcutaneously (60 mg in obese, 20 mg in case of renal failure). Graduated compression stockings were used in case of LMWH or another anticoagulant contraindication. RESULTS: A total of 219 patients were enrolled. We observed six cases of DVT (incidence of 2.7%). The agreement between expected and delivered DVT prophylaxis was 94%. Mean peak anti-Xa activity level was 0.24 (SD, 0.13) IU/mL. There was no significant difference in anti-Xa activity in DVT and non-DVT group. CONCLUSION: A low incidence of DVT was achieved with meticulous adherence to the standard prophylactic protocol. The low incidence of DVT was observed despite low levels of anti-Xa activity. Our findings suggest that enoxaparin dose adjustment based on regular monitoring of anti-Xa activity is unlikely to result in further reduction of DVT incidence in a mixed ICU population. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03286985.
650    _2
$a antikoagulancia $x terapeutické užití $7 D000925
650    _2
$a kritický stav $x terapie $7 D016638
650    12
$a enoxaparin $x terapeutické užití $7 D017984
650    _2
$a heparin nízkomolekulární $7 D006495
650    _2
$a lidé $7 D006801
650    _2
$a jednotky intenzivní péče $7 D007362
650    _2
$a prospektivní studie $7 D011446
650    12
$a žilní tromboembolie $x farmakoterapie $x etiologie $x prevence a kontrola $7 D054556
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Škulec, Roman, $u Faculty of Medicine in Hradec Kralove, Charles University in Prague and University Hospital Hradec Kralove, Czech Republic $u Deartment of Anesthesiology, Perioperative Medicine and Intensive Care Masaryk Hospital, J.E. Purkinje University, Usti nad Labem, Czech Republic $u Faculty of Health Studies, J.E. Purkinje University, Usti nad Labem, Czech Republic $u Department of Anesthesiology and Intensive Care, Faculty of Medicine in Hradec Kralove, Charles University in Prague and University Hospital Hradec Kralove, Czech Republic $u Emergency Medical Service of the Central Bohemian Region, Czech Republic $d 1972- $7 xx0071053
700    1_
$a Jobanek, Jakub $u Deartment of Anesthesiology, Perioperative Medicine and Intensive Care Masaryk Hospital, J.E. Purkinje University, Usti nad Labem, Czech Republic
700    1_
$a Černý, Vladimír, $u Deartment of Anesthesiology, Perioperative Medicine and Intensive Care Masaryk Hospital, J.E. Purkinje University, Usti nad Labem, Czech Republic $u Faculty of Health Studies, J.E. Purkinje University, Usti nad Labem, Czech Republic $u Center for Research and Development, Department of Anesthesiology and Intensive Care, Faculty of Medicine in Hradec Kralove, Charles University in Prague, Hradec Kralove, Czech Republic $u Department of Anesthesia, Pain Management and Perioperative Medicine, Dalhousie University, Halifax, Canada $u Constantine the Philosopher University in Nitra, Faculty of Social Sciences and Health Care, Slovak Republic $d 1960- $7 nlk19990074192
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $x 1213-8118 $g Roč. 166, č. 2 (2022), s. 204-210
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34042098 $y Pubmed
910    __
$a ABA008 $b A 1502 $c 958 $y p $z 0
990    __
$a 20220602 $b ABA008
991    __
$a 20230308093747 $b ABA008
999    __
$a ok $b bmc $g 1824803 $s 1165769
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 166 $c 2 $d 204-210 $e 20210527 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
LZP    __
$b NLK198 $a Pubmed-20220602

Find record

Citation metrics

Archiving options